Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD IL-2 and Nivolumab in Metastatic Clear Cell RCC
NCT02989714Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and aldesleukin in clear cell renal cell carcinoma (ccRCC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Number of Patients With Grade 3 and Grade 4 Adverse Events of Interest at 28 days and Number of Patients That Respond to Treatment at 12 weeks. Started Mar 2017; status: completed.
02
Drugs
nivolumabaldesleukin
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02989714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989714.